Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dentsply Sirona (XRAY) Non-Current Deferred Tax Liability (2016 - 2025)

Dentsply Sirona (XRAY) has disclosed Non-Current Deferred Tax Liability for 17 consecutive years, with $95.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deferred Tax Liability fell 50.78% year-over-year to $95.0 million, compared with a TTM value of $95.0 million through Sep 2025, down 50.78%, and an annual FY2024 reading of $129.0 million, down 43.42% over the prior year.
  • Non-Current Deferred Tax Liability was $95.0 million for Q3 2025 at Dentsply Sirona, down from $109.0 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $668.0 million in Q4 2021 and bottomed at $95.0 million in Q3 2025.
  • Average Non-Current Deferred Tax Liability over 5 years is $279.1 million, with a median of $249.0 million recorded in 2023.
  • The sharpest move saw Non-Current Deferred Tax Liability skyrocketed 69.97% in 2021, then tumbled 57.04% in 2022.
  • Year by year, Non-Current Deferred Tax Liability stood at $668.0 million in 2021, then crashed by 57.04% to $287.0 million in 2022, then dropped by 20.56% to $228.0 million in 2023, then tumbled by 43.42% to $129.0 million in 2024, then decreased by 26.36% to $95.0 million in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for XRAY at $95.0 million in Q3 2025, $109.0 million in Q2 2025, and $134.0 million in Q1 2025.